Ergodan

Quick links to important sections

Ergodan

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ergodan

Quick Facts

Property Description
Active ingredient Ergotamine and Caffeine
Form Tablet and Rectal suppository
Pharmacological class Antimigraine Agent / Ergot Alkaloid
Common use Acute vascular headache treatment
Origin Derived (Ergotamine is fungus-derived)

What Type of Combination Medication Is Ergodan?

Ergodan is medically defined as a fixed-dose combination medication that belongs to the therapeutic category of antimigraine agents. It combines two distinct active substances: the potent ergot alkaloid Ergotamine and the central nervous system stimulant Caffeine. This two-component nature means that Ergodan utilizes a synergistic approach to treatment, distinguishing it from single-ingredient pain relievers. The Ergotamine component is a derivative substance, meaning it is chemically sourced from compounds found in the Claviceps purpurea fungus. Ergotamine is in a class of medications called ergot alkaloids. This classification identifies the medicine's primary chemical family, which is utilized for treating head pain. Other well-known combination products containing this formulation include Cafergot and Migergot.

What Are the Available Forms and Primary Therapeutic Goal?

The general therapeutic goal of Ergodan is the acute treatment of severe migraine and related vascular headaches. The product is typically applied during the initial phases of a vascular headache episode. Ergodan is supplied as both an oral tablet and a rectal suppository, allowing administration via the oral and rectal routes. This dual availability is clinically recognized for its significance to patients whose symptoms include nausea or vomiting, which can impair the reliable absorption of oral medication. The combination is essential to its design: the Caffeine component significantly enhances the rate of Ergotamine absorption, ensuring the medication works faster to address the underlying vascular changes. The combination is intended to efficiently target the severe, intense pain associated with these types of acute episodes.

Regulatory References

  1. MedlinePlus, NIH
  2. NCBI StatPearls, NIH

What side effects are possible with Ergodan?

Possible Side Effects and Safety Information

The safety profile for the Ergotamine/Caffeine combination is documented by regulatory bodies, classifying potential events primarily into categories of frequency and affected organ systems. The profile is characterized by the potential for both common, non-serious physiological reactions and rare, serious vascular risks linked to the ergotamine component.

Adverse Reaction Classifications

Official labels group adverse reactions by affected System-Organ Class (SOC), including Gastrointestinal Disorders, Vascular Disorders, Nervous System Disorders, and Cardiac Disorders.

Classification Examples of Reactions
Common Nausea, vomiting, and dizziness
Uncommon Paresthesia (tingling/numbness), peripheral vasoconstriction, pain in the extremities

Serious Adverse Reactions and Safety Constraints

The regulatory documentation emphasizes the risk of Ergotism, a severe vasoconstrictive condition that can lead to peripheral or cerebral ischemia. Rare but serious fibrotic changes, including retroperitoneal, pleuropulmonary, and cardiac valvular fibrosis, are also officially documented.

Safety constraints require the medicine to be contraindicated in individuals with pre-existing conditions such as Coronary Artery Disease, Peripheral Vascular Disease, and uncontrolled hypertension. Use is also strictly prohibited in the presence of severe hepatic or renal impairment.

Exposure and Population-Specific Notes

The risk of fibrotic complications is associated with long-term continuous use or high cumulative doses. Furthermore, the combination is contraindicated during pregnancy due to the oxytocic potential for fetal harm. Safety is not established in pediatric patients, and use is generally not recommended for older adults.

Safety Profile Summary

This structured safety information formally communicates the full spectrum of risk, from high-frequency, temporary effects to serious, low-frequency vascular pathologies, defining the mandatory physiological conditions and exposure limits under which the medicine must not be used.

Overdose and Emergency Response

The official regulatory documentation for Ergodan (Ergotamine/Caffeine) overdose defines a severe risk associated with acute ergot toxicity, or ergotism. Documented manifestations include prominent gastrointestinal distress, such as persistent nausea and vomiting, alongside neurological symptoms like dizziness, confusion, and potential for seizures. Circulatory disturbances are a major concern, often presenting as tachycardia or bradycardia, and blood pressure changes.

The most critical documented outcome is intense and prolonged peripheral vasoconstriction. This condition, which defines ergotism, can lead to tissue ischemia. This ischemia carries the risk of severe, life-threatening complications, specifically myocardial infarction, cerebral ischemia, or the progression to gangrene of the extremities. Regulatory guidance mandates that immediate medical attention must be sought if an overdose is suspected. Specifically, emergency services must be contacted if the individual has collapsed, experienced a seizure, or cannot be aroused.

Management is strictly supportive and symptomatic, as no specific antidote is known. Officially described procedures include the administration of activated charcoal and the use of specific agents, such as vasodilators, to treat severe vasospasm. Continuous cardiac and peripheral circulation monitoring is required during observation. Regulatory documents also note that patients with impaired hepatic or renal function have an increased risk for toxicity and prolonged effects.

Therapeutic Uses of Ergodan

What Ergodan Treats: Main Uses and Benefits

The primary role of the Ergotamine/Caffeine combination is acute symptomatic support for conditions characterized by episodic, severe symptom patterns. As an acute therapeutic intervention, the medication is commonly used across conditions presenting with intense, throbbing head pain, primarily migraine headaches and related vascular headaches, including cluster headaches.

This formulation is used to address pronounced symptoms when acute manifestations become disruptive. The medication is relevant in clinical settings marked by heightened patient distress, and may assist with coping during difficult symptomatic periods. The overall benefit is to provide supportive relief when symptoms create noticeable physiological strain. “The treatment is applied to ease challenging symptoms, supporting the patient during episodes of heightened discomfort.” This support is particularly useful when symptoms of pain become difficult to tolerate or when associated nausea and vomiting would interfere with the reliable use of oral medication.


Quick Fact: Relief for Acute Vascular Headaches
Primary Use: Acute symptomatic support for migraine and vascular headache episodes.
Symptom Focus: Intense, throbbing pain and associated functional strain.
Contextual Benefit: Relevant when symptoms like nausea or vomiting affect the use of oral medication.

Regulatory References

  1. DailyMed official drug label from the National Institutes of Health

Eligibility and Restrictions for Use

Official Population Eligibility and Restrictions

Ergodan (Ergotamine and Caffeine) is subject to strict regulatory rules that define which populations may use the medicine and which are absolutely excluded. These rules are primarily based on the serious vasoconstrictive risk associated with the ergotamine component, as documented in official government labeling (FDA, NIH, EMA-equivalent documents).

Contraindicated (Must Not Use) Populations
Pregnancy and Lactation: Use is strictly prohibited due to oxytocic effects on the fetus and known excretion into breast milk [FDA Label].
Vascular Conditions: Contraindicated in patients with Coronary Artery Disease, Peripheral Vascular Disease, uncontrolled hypertension, or other ischemic diseases.
Organ Failure: Use is prohibited for patients with severe hepatic or severe renal impairment.
Specific Co-medications: Contraindicated with potent CYP3A4 inhibitors (e.g., certain macrolide antibiotics and protease inhibitors) due to the risk of life-threatening acute ergot toxicity [NIH DailyMed].
Restricted or Conditional Use
Age Groups: Safety and efficacy have not been established in the pediatric population (under 18 years). Use in older adults (over 65) is generally not recommended [NAFDAC SmPC].
Use Duration: The medicine is not recommended for chronic daily administration or for prophylactic treatment, as it is only indicated for acute, intermittent use [FDA Label].

Official regulatory documents classify use in patients with underlying vascular disease, severe organ failure, or during pregnancy as an Absolute Contraindication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Ergodan (Ergotamine/Caffeine) is primarily determined by two core regulatory constraints: the metabolism of Ergotamine via the CYP3A4 enzyme and its inherent vasoconstrictive properties. These factors lead to specific restrictions and formal contraindications documented in prescribing information.

Major Contraindicated Combinations

Category Reason for Contraindication Constraint Type
Potent CYP3A4 Inhibitors (e.g., Macrolide Antibiotics, HIV Protease Inhibitors, Azole Antifungals) Significantly increased Ergotamine plasma concentration, risking acute ergot toxicity (ergotism). Absolute Prohibition
5-HT₁ Receptor Agonists (Triptans) Additive or synergistic vasoconstriction, risking prolonged vasospasm. Absolute Prohibition
Other Vasoconstrictors / Organic Nitrates Enhanced hypertensive risk or pharmacodynamic antagonism of the nitrate's effect. Absolute Prohibition

Administration Requirements and Exposure Modification

Co-administration with 5-HT₁ Receptor Agonists is strictly restricted, requiring a mandatory minimum separation of 24 hours. Exposure to Ergotamine may also be increased by moderate CYP3A4 inhibitors, including substances like Grapefruit juice. Furthermore, the official labeling notes that the drug is formally contraindicated in patients with severe hepatic or renal impairment. This population-specific restriction is due to reduced drug clearance, which heightens the risk of drug accumulation and associated toxicity.

Mechanism of Action

℅ Dual Modulation of Vascular Tone and Neural Signaling

The mechanism of Ergodan is defined by the complementary actions of Ergotamine and Caffeine, which engage two critical regulatory systems. Ergotamine functions as an agonist on mathbf5-HT1B and mathbfalpha1 receptors, directly triggering the contraction of cranial blood vessels. Concurrently, it activates mathbf5-HT1D receptors on the trigeminal nerve endings to inhibit the release of pro-inflammatory neuropeptides, thereby modulating the release of neuropeptides at the nerve terminal.


Synergy through Anti-Vasodilatory Action

The component Caffeine enhances this mechanism through its role as a non-selective antagonist of mathbfA1 and mathbfA2A adenosine receptors. By blocking adenosine, an intrinsic biological signal that promotes vasodilation, Caffeine contributes its own vessel-narrowing effect. This combined agonism (Ergotamine) and antagonism (Caffeine) results in a sustained physiological constriction** of the affected vasculature, leading to an alteration of pathway activity within these key systems.


️ Constraint of Non-Selective Receptor Engagement

The mechanism of vasoconstriction is inherently non-selective, as the targeted mathbf5-HT1B and mathbfalpha1 receptors are also present in peripheral tissues. This non-specificity means the drug engages vascular beds throughout the body, not just those in the cranial area. This broad interaction is a key constraint that shapes the drug's overall physiological profile.

Dosage and Administration Information

How to Use Ergodan

Ergodan (Ergotamine and Caffeine) is classified as an intermittent-use agent and is explicitly not intended for chronic daily administration. The primary principle governing its administration is time-critical initiation, where the medication should be taken at the very first sign of an acute episode.

Administration is possible via two approved routes, which also feature different dosage strengths:

  • Oral: Available as a tablet containing 1 mg of Ergotamine and 100 mg of Caffeine.
  • Rectal: Available as a suppository containing 2 mg of Ergotamine and 100 mg of Caffeine.

The suppository form is an option for patients experiencing symptoms such as nausea or vomiting, which may compromise the reliable absorption of oral medication.

Standard Labeled Dosing Regimens

Dosing is structured as an initial amount followed by sequential, smaller doses, all capped by rigid maximums.

Administration Route Initial Dose Subsequent Dose Interval Maximum Dose Per Attack
Oral (Tablet) 2 tablets Every 30 minutes, if needed 6 tablets (6 mg Ergotamine)
Rectal (Suppository) 1 suppository After 1 hour, if needed 2 suppositories (4 mg Ergotamine)

Total cumulative dosage is restricted to a maximum of 10 tablets or 5 suppositories per week. Furthermore, the medication is contraindicated in severe renal or hepatic impairment and is generally not recommended for use in pediatric or geriatric populations, as safety and efficacy have not been established in these groups.

Recent Clinical Evidence

Ergodan: Recent Clinical Evidence

Research has explored the effects of Ergodan, a synthetic ergot alkaloid derivative, across several clinical settings. Studies have focused on its potential association with certain cerebrovascular and cognitive functions.

Key Areas of Investigation

Clinical research has historically examined the agent’s effects in conditions related to circulation and cognition. Trials typically assess changes in neurological function and quality of life measures.

Trial Type Primary Focus Key Outcome Measures in Studies
Phase III RCTs Cerebral blood flow, cognitive impairment Changes in psychometric test scores, clinical assessment scales
Comparative Studies Effect against older agents Comparison of changes in global function and daily activity scales

Study Findings Overview

Cerebrovascular Function: Research investigated whether the administration of the agent was associated with changes in cerebral blood flow parameters, particularly in individuals with age-related vascular changes. Findings have been reviewed by regulators evaluating the data submitted from these trials.

Cognitive Assessment: Studies examined the agent's impact on cognitive functions, such as attention, perception, and memory. In double-blind, randomized studies, some aspects of limb function and geriatric assessment scores were observed to change after treatment with Ergodan or related ergoloid compounds. However, researchers noted that statistically significant changes were often not large in magnitude.

Long-Term Research: The duration of changes in clinical assessment scores has been a subject of research. The long-term research explored whether the agent was associated with improvements in patient measures of quality of life, though definitive conclusions are not yet clear.

Key Studies & References A cognitive training intervention increases resting cerebral blood flow in healthy older adults (Reference for cerebral blood flow assessment methods)

Frequently Asked Questions (FAQ)

Common questions about Ergodan (FAQ)


Q: Do I need to change my diet while taking Ergodan?

Official product information describes an avoidance of consuming grapefruit or grapefruit juice while using this medication. This restriction is due to the potential for grapefruit to increase the amount of Ergodan in your body. General changes to your overall diet are not universally mandated in the regulatory labeling.


Q: How quickly does Ergodan usually start to work after I begin taking it?

Studies and official information indicate that the caffeine component in the combination is described as enhancing the speed at which the ergotamine is absorbed. This enhanced absorption contributes to a faster onset of action, which is relevant for the acute treatment of a vascular headache.


Q: Are there any specific activities or foods I should avoid while using Ergodan?

Official sources specify that grapefruit juice should be avoided due to a potential interaction. Furthermore, because common side effects include dizziness and vertigo, patients who experience these reactions should avoid activities that require full mental focus, such as driving or operating heavy machinery.


Q: What happens if I accidentally take two doses of Ergodan?

Regulatory information provides rigid limits on the maximum amount of medication that is to be taken per headache attack and per week. Taking more than the prescribed amount or taking doses too closely together can increase the risk of serious side effects, including a severe condition called ergotism. Official regulatory information advises that if an overdose is suspected, medical attention should be sought immediately.


Q: What are the possible signs of a serious interaction involving Ergodan?

Serious vasoconstrictive complications are described in the regulatory documents. Official guidance indicates that signs that may suggest a serious event should be reported promptly. These signs include numbness or tingling in the fingers and toes, muscle pain or weakness in the arms and legs, or chest pain.


Q: Can Ergodan affect my ability to drive or operate machinery?

Official regulatory labels list neurological side effects, such as dizziness and vertigo, as possible reactions. Because these reactions can impact coordination and judgment, patients who experience them should avoid activities that require full mental focus, such as driving or operating heavy machinery.


Q: What should I do if I miss a dose of Ergodan?

Ergodan is officially prescribed for the acute, intermittent treatment of a headache episode, and not for chronic daily use. Therefore, standard instructions for a 'missed dose' are typically not applicable to this medication. The medicine is indicated for use only at the onset of an attack.


Q: Is there a generic version of Ergodan available?

Official regulatory and market information confirms that the formulation containing ergotamine tartrate and caffeine has been developed and approved as a generic product by various manufacturers.


Q: Can I take non-prescription pain relievers while I am on Ergodan?

Regulatory documents state that Ergodan is contraindicated with specific types of medicines known as vasoconstrictors because of the risk of enhanced narrowing of blood vessels. The official labeling provides general patient guidance that all medications, including non-prescription ones, should be discussed with a healthcare provider.


Q: Will I have withdrawal symptoms if I stop taking Ergodan?

Regulatory-cited patient information indicates that in cases of indiscriminate use over long periods, discontinuing the medication may lead to withdrawal symptoms. These symptoms are typically described as a rebound headache (also called medication overuse headache).


Q: Can Ergodan cause problems with my sleep?

Due to the presence of caffeine, a central nervous system stimulant, the safety profile of Ergodan includes potential common side effects. These reactions can include restlessness and trouble sleeping (insomnia).


Q: How is Ergodan different from a supplement I might buy over the counter?

Ergodan is formally defined as a fixed-dose combination prescription medication, distinguishing it from supplements available over the counter. It contains the potent ergot alkaloid Ergotamine and Caffeine, and is only available through a prescription from a licensed healthcare provider.


Q: Can Ergodan affect my mood or mental state?

Due to the inclusion of a central nervous system stimulant (caffeine) and its effects on the nervous system, official documentation suggests caution when administering to patients who have a history of certain psychiatric conditions.


Q: If Ergodan is not working for me, how long should I wait before talking to my doctor?

Regulatory-derived patient information suggests that if relief is not experienced from the acute headache attack, patients may need to discuss this with their healthcare team. No specific duration or waiting period is provided in the official labeling.


Q: Is Ergodan a controlled substance?

Official government regulatory classifications indicate that the ergotamine/caffeine combination is a prescription-only medication in the US. However, it is not typically scheduled as a controlled substance under the Drug Enforcement Administration (DEA).


Q: What if I'm taking herbal products or vitamins? Will they interact with Ergodan?

Regulatory guidance states that patients should inform their healthcare provider about all products used, including vitamins and herbal products. The official labeling specifically notes that nicotine use is known to potentiate vasoconstriction, which may increase the risk of an ischemic response.


Q: Does the time of day I take Ergodan matter?

The primary principle for using this medication is time-critical initiation. Official labeling advises that the medication is to be taken at the very first sign of an acute headache attack for maximum effectiveness. The timing relative to the headache onset is the critical factor, rather than the specific time of day.


Q: Does Ergodan have any known interactions with common foods?

Official product information documents a specific interaction with grapefruit juice. The documentation notes that consuming grapefruit juice may increase the concentration of Ergodan in the blood plasma, potentially leading to increased risk of side effects.


Q: Is it possible for Ergodan to stop working over time?

Regulatory information notes that long-term continuous use can lead to dependency on the medication. This dependency can result in the development of a rebound headache (medication overuse headache) upon discontinuation, suggesting a change in the body's response over time.


Q: Are the side effects of Ergodan permanent?

The official safety profile notes that the most serious side effects, such as rare fibrotic changes (e.g., cardiac valvular fibrosis) and the consequences of ergotism, are potentially serious and long-term. This risk is primarily associated with long-term continuous use of the medication.


Q: How long does Ergodan stay in my system after I stop taking it?

Pharmacokinetic data reported in clinical literature indicates that the ergotamine component is metabolized by the liver and has a relatively short half-life of approximately 2 hours. This data describes the rate at which the drug leaves the body.


Q: Is the purpose of Ergodan purely symptomatic relief?

According to regulatory documentation, Ergodan is indicated as a therapy intended to abort or prevent an acute, severe vascular headache episode. It is applied during the initial phases of the attack and is not intended for chronic preventative (prophylactic) therapy.


Q: Can I share my Ergodan prescription with a family member who has the same condition?

Regulatory-derived patient warnings state that this medicine is intended only for the patient prescribed and is not to be shared with others, even if they have the same health condition.


Q: Why do some people need to take Ergodan with food?

Patient information, consistent with regulatory guidelines, states that the tablets can be taken with or without food. There is no official requirement to take the medication with food.


Q: Is it possible to be allergic to Ergodan?

Official documents list Allergic reactions as a potential adverse event within the safety profile. Examples of allergic reactions can include localized edema (swelling) and itching, and there is a specific warning about a yellow dye in the tablet (tartrazine) that may cause allergic reactions.


Q: Does stress or illness change how my body handles Ergodan?

The official label specifies that use is contraindicated in the presence of severe renal (kidney) or hepatic (liver) impairment because these conditions affect how the body handles the medication. External factors like illness or stress are also noted in general medical literature as potential triggers that may influence the timing of a headache attack.


Q: Is Ergodan known to cause dependency?

Regulatory documents advise that if this medication is used in excessive amounts or for a long period, it may become habit-forming. This dependency can potentially lead to serious unwanted effects.

How should Ergodan be stored and disposed of?

How to Store and Dispose of Ergodan?

The storage requirements for Ergodan (Ergotamine and Caffeine) are strictly defined by regulatory guidelines and depend on the product's dosage form.


Required Storage Conditions

Dosage Form Temperature Requirement Additional Protection
Oral Tablets Controlled Room Temperature: 20 to 25 C (68 to 77 F) Store in a tight, light-resistant container.
Rectal Suppositories Refrigeration: 2 to 8 C (36 to 46 F) Do not freeze and protect from heat.

Handling and Disposal

To maintain stability, all forms of the medicine must be protected from light and moisture. The official labeling mandates that Ergodan must be kept out of the reach of children. Unused or expired medication must not be kept. Disposal should not involve flushing or throwing the product into household waste; individuals must follow the correct disposal procedure as instructed by a healthcare professional or pharmacist, in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ergodan found in:

A-Z Index: